ATYR
No price yet
Announcements
Nothing here yet
Daily updates
- aTyr Pharma Reports Preclinical Anti-Fibrotic Findings for ATYR0101Oct 14, 2026
- aTyr Pharma is evaluating efzofitimod in the EFZO-CONNECT Phase 2 trial for systemic sclerosis-associated interstitial lung disease, with topline data expected in Q1 2027. The study is assessing safety, tolerability, and clinical efficacy, following interim findings showing improvements in modified Rodnan Skin Score at Week 12.Oct 4, 2026
- aTyr aligned with the FDA on a Phase 3 efzofitimod protocol for chronic symptomatic pulmonary sarcoidosis with restrictive lung disease.Sep 25, 2026
- aTyr aligned with the FDA on a Phase 3 efzofitimod protocol for chronic symptomatic pulmonary sarcoidosis with restrictive lung disease, establishing Week 48 FVC change as the primary endpoint in a planned 54-week study of up to 372 patients.Sep 24, 2026
FDA designations
Nothing here yet
News
- aTyr Pharma announces a research collaboration with Montefiore EinsteinOct 19, 2026
- aTyr Pharma announces alignment with FDA on the Phase 3 study design for efzofitimod in pulmonary sarcoidosisSep 24, 2026
- aTyr Pharma provided an update on the timing of the regulatory response for its planned Phase 3 study of efzofitimod in pulmonary sarcoidosisSep 7, 2026
- aTyr Pharma scheduled FDA Type C meeting for efzofitimod in pulmonary sarcoidosisFeb 4, 2026
- aTyr Pharma presents additional findings from Phase 3 EFZO-FIT™ study in late-breaking oral abstract at European Respiratory Society (ERS) Congress 2025Sep 30, 2025